Switching to a new anti-VEGF improves visual outcomes in a patient with recalcitrant nAMD
The patient is a 62-year-old male who started to experience blurred vision in his left eye in November 2015. Previously, he was diagnosed with neovascular age-related macular degeneration (nAMD) in the right eye (polypoidal choroidal vasculopathy [PCV] subtype) in January 2012, which is currently maintained with Q4W intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent, aflibercept. A treat-and-extend (T&E) regimen with aflibercept could not be achieved with the right eye since nAMD recurred every time treatment intervals were increased beyond Q4W. As of May 2022, he has received in excess of 70 intravitreal injections of aflibercept to the right eye, which has a stable but poor visual acuity of 1/60.

New Molecule

3 New

New Indication

2 New

New Dosage Form

1 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in